Travere: No AdCom, No Problem - Targeting Big Revenues With FSGS Approval (NASDAQ:TVTX)

Travere Therapeutics, Inc. stock upgraded to Buy: FDA momentum, Filspari's growth, and financials signal potential blockbuster gains. Click for my TVTX update.